New options in prostate cancer

Although prostate cancer is one of the rare cancers to benefit from tools that can be easily applicable to early diagnosis (PSA test and biopsy), the majority of countries do not recommend general or systematic screenings. In fact, their introduction would lead to an increase in radical therapies, in their potential side effects or in overtreatment. This represents a loss of opportunity for patients who are not screened and who could benefit from an earlier diagnosis.

Focal therapy for low-risk prostate cancer constitutes a third therapeutical option, thereby expanding physicians’ therapeutic arsenal which currently consists of radical therapy and active surveillance.
This new option treats prostate in a targeted manner, thereby reducing the risk of damaging the surrounding nerves and muscles, the urinary sphincter, the bladder or the rectum.